CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

General Public cohortWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000857 Olfaction Disorders NIH 0.29

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000458 Anosmia HPO 0.29

There is one clinical trial.

Clinical Trials

1 FORECAST Study: Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste

The FORECAST Study is an observational cohort study looking at two cohorts of patients presenting with COVID-19: a general public cohort, aiming to investigate if new loss or reduced sense of smell and/or taste are early signs of COVID-19 and a hospital cohort, which will investigate if taste/smell changes can predict the clinical course of a COVID-19 infection.

NCT04377815 COVID-19 Anosmia Other: General Public cohort
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: percentage of people who report loss/reduced sense of smell or taste

Measure: Percentage of people reporting changes in smell/taste

Time: 4 weeks

Description: to compare the case mortality rate in COVID-19 patients who experienced smell/taste changes compared to mortality in those who did not experience smell/taste changes.

Measure: mortality rate

Time: through study completion, an average of 1 year

Secondary Outcomes

Description: To identify the percentage of people who report changes in taste and/or smell before developing either fever or persistent cough who are positive for SARS-CoV-2 IgM and IgG

Measure: Percentage of people with change in smell/taste before other symptoms

Time: 4 weeks

Description: To examine the proportion of other COVID-19 linked symptoms in people with smell and/or taste change who are positive positive for SARS-CoV-2 IgM and IgG who never develop fever and/or cough.

Measure: proportion of other COVID-19 linked symptoms in people with smell and/or taste change

Time: 4 weeks

Description: To determine the percentage of people whose smell and/or taste symptoms persist for greater than 4 weeks in people who are positive for SARS-CoV-2 IgM and IgG

Measure: Percentage of people with persistent changes in smell and/or taste

Time: 12 weeks

Description: To determine the percentage of patients who report loss/decrease in sense of smell and/or taste changes before or in the absence of other symptoms of COVID-19, who are admitted to hospital with COVID-19

Measure: Percentage of hospitalisation

Time: 12 weeks

Description: To investigate whether loss/reduced sense of smell and/or taste are associated with the course of illness and outcomes in COVID-19

Measure: co-morbidities association

Time: through study completion, an average of 1 year

Description: Assessing the prevalence of previous loss/decrease in sense of smell and/or taste changes in patients admitted to secondary care with COVID-19 infection.

Measure: prevalence of changes in smell/taste

Time: through study completion, an average of 1 year

Description: Correlating the presence of loss/decrease in sense of smell and/or taste changes to clinical outcomes including case fatality rate.

Measure: clinical outcomes

Time: through study completion, an average of 1 year

Related HPO nodes (Using clinical trials)

HP:0000458: Anosmia
Genes 67
PROKR2 SMCHD1 SEMA3E ARNT2 SOX3 CHD7 PROK2 PROKR2 NSMF PHYH ARSL NSMF ANK1 ADCY3 FGFR1 DCC FGF17 OTX2 SOX10 SEMA3A PEX7 SHH ANOS1 FGFR1 TACR3 PEX7 FGFR1 SOX10 HESX1 SOX10 KISS1R HESX1 FGF8 SMCHD1 DNAI1 FGF8 WDR11 PHYH TAC3 SEMA3A KISS1 CHD7 WDR11 FLRT3 PROKR2 ATP13A2 KISS1R IL17RD CCDC141 CHD7 CCDC141 HS6ST1 SOX2 GNRH1 ANOS1 SOX10 SCN9A SEMA3E FEZF1 IL17RD SPRY4 PEX7 CHD7 DUSP6 FEZF1 MFN2 PROK2
Protein Mutations 0
SNP 0